Dihydroxystilbenes prevent azoxymethane/dextran sulfate sodium-induced colon cancer by inhibiting colon cytokines, a chemokine, and programmed cell death-1 in C57BL/6J mice.


Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
05 Nov 2020
Historique:
received: 24 02 2020
revised: 25 07 2020
accepted: 29 07 2020
pubmed: 8 8 2020
medline: 15 5 2021
entrez: 8 8 2020
Statut: ppublish

Résumé

The incidence of colon cancer increased worldwide in 2019 and its treatment is urgent from a quality of life perspective. A relationship has been reported between elevated numbers of tumor-associated macrophages (TAMs) in the tumor microenvironment and a poor prognosis in cancer patients, and M2 TAMs have been shown to promote tumor growth by immunosuppression through the stimulation of programmed death-1 (PD-1, an immune check point receptor), interleukin (IL)-1β, and monocyte chemoattractant protein (MCP)-1. We herein examined the effects of three synthetic dihydroxystilbenes (2,3-, 3,4-, and 4,4'-dihydroxystilbenes) on colon carcinogenesis, colon tumor growth, and colon cytokines (IL-1β, IL-6, and tumor necrosis factor (TNF)-α), a chemokine (MCP-1), vascular endothelial growth factor (VEGF), and PD-1 levels in azoxymethane (AOM) plus dextran sulfate sodium (DSS)-treated C57BL/6J mice. The three dihydroxystilbenes inhibited colon carcinogenesis and tumor growth as well as increases in colon IL-1β, IL-6, MCP-1, and PD-1 levels in AOM/DDS-treated mice (in vivo). The three dihydroxystilbenes also suppressed COX-2 expression in colon tumors (in vivo). The results obtained also revealed that the three dihydroxystilbenes inhibited PD-1 elevations in M2-THP-1 macrophages (in vitro). Therefore, the inhibition of AOM/DSS-induced colon carcinogenesis and colon tumor growth by 2,3-, 3,4-, and 4,4'-dihydroxystilbenes appears to be due to the suppression of M2 TAM differentiation and activation and PD-1 expression (immunosuppression) via reductions in COX-2 expression levels in the colon tumor microenvironment.

Identifiants

pubmed: 32758571
pii: S0014-2999(20)30537-9
doi: 10.1016/j.ejphar.2020.173445
pii:
doi:

Substances chimiques

Carcinogens 0
Ccl2 protein, mouse 0
Chemokine CCL2 0
Chemokines 0
Cyclooxygenase 2 Inhibitors 0
Cytokines 0
Dihydrostilbenoids 0
Dextran Sulfate 9042-14-2
Azoxymethane MO0N1J0SEN

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

173445

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Yoshiyuki Kimura (Y)

Department of Functional Biomedicine, Graduate School of Medicine, Ehime University, Japan. Electronic address: yokim@m.ehime-u.ac.jp.

Maho Sumiyoshi (M)

Department of Functional Biomedicine, Graduate School of Medicine, Ehime University, Japan.

Takeshi Kiyoi (T)

Division of Analytical Bio-Medicine, The Advanced Research Support Center (ADRES), Ehime University, Shigenobu-cho, Toon City, Ehime, 791-0295, Japan.

Kimiye Baba (K)

Department of Pharmacognosy, Osaka University of Pharmaceutical Sciences, Takatsuki City, Osaka, 569-1094, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH